Hepatitis B Virus: A Call to Action in 2024

Cody A. Chastain, MD, FACP, FIDSA
Associate Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center
February 14, 2024
Disclosures or Conflicts of Interest

- No personal disclosures or conflicts of interest
SE AETC Funding Disclosure

- This program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1OHA30535 as part of an award totaling $4.2m. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.

- Funding for this presentation was made possible by cooperative agreement U1OHA30535 from the Health Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.
Southeast AIDS Education and Training Center (SE AETC)
What is your professional role?

- APRN: 2
- Case Manager: 2
- Nurse: 18
- PA: 0
- Pharmacist: 4
- Physician: 4
- Public Health: 20
- Social Worker: 2
- OTHER: 5
What word(s) come to mind when you think of hepatitis B virus (HBV)?
100 responses
Case: Introducing Hep Bee

- 39 y/o engineer from China who has been referred to clinic for a positive HBV test result
- Denies any prior medical history or symptoms related to hepatitis
- Unaware of diagnosis prior to recent testing performed at time of primary care intake
- ALT 50 U/L [upper limit of normal (ULN) per lab 40]
- AST 45 U/L (ULN per lab 40)
- HBV serology reveals:
  - Anti-HBs negative
  - Total Anti-HBc negative
  - HBsAg positive
  - HBeAg negative
  - Anti-HBe positive
- HBV DNA ~4,500 IU/mL
Zooming In: Clinical Questions

- How do we classify Mr. Bee’s HBV infection?
- Should Mr. Bee be treated?
- What treatment options are available for Mr. Bee now and anticipated in the future?
Zooming Out: Points to Ponder

- How impactful is HBV today both globally and domestically?
- Who should be screened and treated for HBV?
- How is treatment for HBV evolving, and how will that impact other aspects of clinical care and scientific investigation?
Goal

- To raise awareness of the state of hepatitis B virus (HBV), evolving screening and treatment recommendations, and future clinical and scholarly opportunities
Objectives

At the end of this grand rounds, you will be able to:

- Describe the evolving epidemiology of HBV globally and in the United States;

- Apply current recommendations for HBV screening, management, and treatment;

- Discuss new HBV treatment and management strategies and their implications for clinical and scholarly interventions.
Take Home Points

1. HBV has a huge health impact on global and domestic populations, who are often at-risk and underserved.

2. Universal HBV screening is now recommended, along with more inclusive HBV vaccination guidelines.

3. Evolving HBV treatment algorithms and new antiviral therapies are transforming clinical care and the opportunities for clinical, research, and scholarly activity.
HBV Outline

- Evolving Epidemiology
- Current Management of HBV
- Evolving Approaches to Management and Treatment
HBV Outline

- Evolving Epidemiology
- Current Management of HBV
- Evolving Approaches to Management and Treatment
Rank these chronic viral infections based on the number of deaths attributed globally each year? (1st = Most, 3rd = Least)

1st: Hepatitis B
2nd: Hepatitis C
3rd: Human Immunodeficiency Virus
As of 2019 per WHO:
~296 million chronic HBV infections worldwide
~1.5 million new infections each year
~820,000 deaths worldwide each year

(In comparison, HCV caused ~290,000 deaths in 2019 while HIV caused ~690,000 deaths in 2022)
Figure 12 - Worldwide Deaths and Projected Deaths from Chronic Viral Hepatitis as Compared with Deaths from Tuberculosis, Human Immunodeficiency Virus (HIV) Infection, and Malaria.
So, why don’t we talk about this more?
https://www.hepatitisb.uw.edu

Figure 10 - Chronic Hepatitis B Virus: Global Prevalence Estimates, by World Health Organization Regions, 2019

US prevalence estimates range from ~850,000 to ~2,200,000 (predominantly foreign-born)
Take Home Points

1. HBV has a huge health impact on global and domestic populations, who are often at-risk and underserved.

2. Universal HBV screening is now recommended, along with more inclusive HBV vaccination guidelines.

3. Evolving HBV treatment algorithms and new antiviral therapies are transforming clinical care and the opportunities for clinical, research, and scholarly activity.
How can we better identify people with HBV?
Groups at Increased Risk for HBV (CDC)

- Persons currently or formerly incarcerated in jail, prison, or another detention setting
- Persons with current or past sexually transmitted infections (STIs) or multiple sex partners
- Persons with current or past hepatitis C virus (HCV) infection
- Persons born in regions with an HBV prevalence equal to or greater than 2%
- US-born persons who were not vaccinated as infants and whose parents were born in a region of high HBV prevalence (equal to or greater than 8%)
- Persons with HIV infection
- Persons with current or past injection drug use
- Men who have sex with men
- Infants born to people who are HBsAg-positive
- Household contact with a person who has HBV infection
- Needle-sharing or sexual contacts of persons with known HBV infection
- Patients receiving predialysis, hemodialysis, peritoneal dialysis, or home dialysis
- Persons with elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels of unclear etiology
- Persons who request HBV testing due to the potential reluctance to disclose stigmatizing risk factors
### Risk Behaviors/Exposures

<table>
<thead>
<tr>
<th>Risk Behaviors/Exposures</th>
<th>Risk identified*</th>
<th>No risk identified</th>
<th>Risk data missing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection drug use</td>
<td>402</td>
<td>713</td>
<td>1,042</td>
</tr>
<tr>
<td>Multiple sexual partners</td>
<td>124</td>
<td>512</td>
<td>1,521</td>
</tr>
<tr>
<td>Surgery</td>
<td>91</td>
<td>688</td>
<td>1,378</td>
</tr>
<tr>
<td>Sexual contact $^6$</td>
<td>46</td>
<td>498</td>
<td>1,613</td>
</tr>
<tr>
<td>Needlestick</td>
<td>36</td>
<td>742</td>
<td>1,379</td>
</tr>
<tr>
<td>Men who have sex with men $^6$</td>
<td>64</td>
<td>281</td>
<td>952</td>
</tr>
<tr>
<td>Household contact (non-sexual) $^6$</td>
<td>9</td>
<td>535</td>
<td>1,613</td>
</tr>
<tr>
<td>Dialysis patient</td>
<td>31</td>
<td>786</td>
<td>1,340</td>
</tr>
<tr>
<td>Occupational</td>
<td>1</td>
<td>970</td>
<td>1,186</td>
</tr>
<tr>
<td>Transfusion</td>
<td>1</td>
<td>809</td>
<td>1,347</td>
</tr>
</tbody>
</table>

* Reported confirmed cases.

$^6$ Reported cases may include more than one risk behavior/exposure. Case reports with at least one of the following risk behaviors/exposures reported 6 weeks to 6 months prior to symptom onset or documented seroconversion if asymptomatic: 1) injection drug use; 2) multiple sexual partners; 3) underwent surgery; 4) men who have sex with men; 5) sexual contact with suspected/confirmed hepatitis B case; 6) sustained a percutaneous injury; 7) household contact with suspected/confirmed hepatitis B case; 8) occupational exposure to blood; 9) dialysis; and 10) transfusion.

$^6$ Cases with more than one type of contact reported were categorized according to a hierarchy: (1) sexual contact; (2) household contact (nonsexual).

$^6$ A total of 1,297 acute hepatitis B cases were reported among males in 2020.

HBV Testing and Diagnosis Cascade

- In the REACH US cohort, only 39.2% tested for HBV among 53,896 racial and ethnic minority individuals.

- In Kaiser Permanente Hawaii, only 28.3% tested among 41,263 adults of Asian-Pacific Islander ethnicity.

- Of 511,029 commercially insured adults modeled to have HBV:
  - Only 18.6% diagnosed
  - Of those with cirrhosis, only 34.8% treated
  - Of those with HCC, only 48.6% treated

# CDC Department of Viral Hepatitis Strategic Plan 2025

<table>
<thead>
<tr>
<th>CDC Goals</th>
<th>Baseline</th>
<th>~2025 Target</th>
<th>~2030 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>New HBV infections</td>
<td>22,200</td>
<td>≤18,000</td>
<td>≤2200</td>
</tr>
<tr>
<td>Awareness of HBV infection</td>
<td>32%</td>
<td>≥50%</td>
<td>≥90%</td>
</tr>
<tr>
<td>Engagement in HBV care</td>
<td>26%</td>
<td>≥40%</td>
<td>≥80%</td>
</tr>
<tr>
<td>HBV-related deaths/100,000 persons</td>
<td>0.46</td>
<td>≤0.37</td>
<td>≤0.16</td>
</tr>
</tbody>
</table>
Rationale For Universal One-Time Adult HBV Screening

- Reduce stigma
- Simplify screening/testing
- Timely diagnosis
- Facilitate linkage to care
- Align testing with vaccination
- Cost-effective

Conners EE et al. MMWR 2023.
Summary of 2023 HBV screening and testing recommendations

Screen all adults aged 18 years and older at least once in their lifetime using a triple panel test

Screen pregnant people for hepatitis B surface antigen (HBsAg) during each pregnancy regardless of vaccination status and history of testing

Expand periodic risk-based testing to include people incarcerated, people with a history of sexually transmitted infections or multiple sex partners, and people with hepatitis C virus infection

Test anyone who requests HBV testing regardless of disclosure of risk

Update: All adults should be tested at least once for hepatitis B. Have you been tested?
ACIP HBV Vaccination Recommendations 2022

- Infants

- Children age 18 years and younger

- Adults age 19 to 59 years

- Adults age 60 years and older with risk factors for HBV
Figure 1 - Incorporating HBV Screening and Testing into a Clinic Workflow: Nonpregnant Adults Aged ≥18 Years without a Known History of HBV Infection

Take Home Points

1. HBV has a huge health impact on global and domestic populations, who are often at-risk and underserved.

2. Universal HBV screening is now recommended, along with more inclusive HBV vaccination guidelines.

3. Evolving HBV treatment algorithms and new antiviral therapies are transforming clinical care and the opportunities for clinical, research, and scholarly activity.
HBV Outline

- Evolving Epidemiology
- **Current Management of HBV**
- Evolving Approaches to Management and Treatment
Case: Treating Hep Bee

- 39 y/o engineer from China who has been referred to clinic for a positive HBV test result
- Denies any prior medical history or symptoms related to hepatitis
- Unaware of diagnosis prior to recent testing performed at time of primary care intake
- ALT 50 U/L [upper limit of normal (ULN) per lab 40]
- AST 45 U/L (ULN per lab 40)
- HBV serology reveals:
  - Anti-HBs negative
  - Total Anti-HBc negative
  - HBsAg positive
  - HBeAg negative
  - Anti-HBe positive
- HBV DNA ~4,500 IU/mL
How would you manage Mr. Bee?

- Monitor: 41
- Treat: 10
Figure 3 - Hepatitis B Disease Phases
This illustration shows the relationship between different hepatitis B immune phases and fluctuations in HBV DNA and serum alanine aminotransferase (ALT) levels.

Illustration: David H. Spach, MD
<table>
<thead>
<tr>
<th>Variable</th>
<th>HBeAg-Positive Chronic HBV Infection</th>
<th>HBeAg-Positive Chronic Hepatitis B</th>
<th>HBeAg-Negative Chronic HBV Infection</th>
<th>HBeAg-Negative Chronic Hepatitis B</th>
<th>“Gray Zone”</th>
<th>Occult Hepatitis B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other phase names</td>
<td>Immune tolerant</td>
<td>Immune (re)active</td>
<td>Inactive carrier state</td>
<td>HBeAg-negative disease</td>
<td>Indeterminate</td>
<td>None</td>
</tr>
<tr>
<td>Serologic testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Quantitative HBsAg</td>
<td>3.5–4.5</td>
<td>3.5–4.5</td>
<td>2.5–3.5</td>
<td>2–3</td>
<td>2–3</td>
<td>Negative</td>
</tr>
<tr>
<td>(log_{10} IU/ml)†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBeAg</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>HBe antibodies</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>May be positive</td>
</tr>
<tr>
<td>HBV DNA (IU/ml)</td>
<td>Typically &gt;10³</td>
<td>Typically &gt;10³ to 10⁷</td>
<td>&lt;10³</td>
<td>Typically &gt;10⁷ to ≤10⁹</td>
<td>2 x 10⁹ (3.3 log_{10}) to 2 x 10⁹ (4.3 log_{10})</td>
<td>Low, at detection limit</td>
</tr>
<tr>
<td>Alanine aminotransferase</td>
<td>Near ULN</td>
<td>Elevated</td>
<td>Near ULN</td>
<td>Elevated</td>
<td>Fluctuates near ULN</td>
<td>Near ULN</td>
</tr>
<tr>
<td>Histologic features on liver biopsy</td>
<td>Minimal necroinflammation or fibrosis</td>
<td>Moderate-to-severe necroinflammation and varying degrees of fibrosis</td>
<td>Minimal necroinflammation and fibrosis</td>
<td>Moderate-to-severe necroinflammation or fibrosis</td>
<td>Minimal or low necroinflammation</td>
<td>Usually minimal or low necroinflammation; fibrosis can be present</td>
</tr>
<tr>
<td>cccDNA (assumed copy no./cell)‡</td>
<td>Relatively high</td>
<td>Relatively high</td>
<td>Relatively low, or transcriptional activity</td>
<td>Relatively low, or transcriptional activity</td>
<td>Relatively low, or transcriptional activity</td>
<td>Data uncertain</td>
</tr>
<tr>
<td>Integrated HBV DNA§</td>
<td>Present</td>
<td>Present</td>
<td>Present and accounts for majority of HBsAg</td>
<td>Present and accounts for majority of HBsAg</td>
<td>Present</td>
<td>Present</td>
</tr>
<tr>
<td>HBeAg level</td>
<td>High</td>
<td>High</td>
<td>Low or undetected</td>
<td>Lower than HBeAg-positive states</td>
<td>May be detected</td>
<td>Data not available</td>
</tr>
<tr>
<td>HBV RNA level</td>
<td>High</td>
<td>High</td>
<td>Low or undetected</td>
<td>Lower than HBeAg-positive states</td>
<td>May be detected</td>
<td>Data not available</td>
</tr>
</tbody>
</table>

* The abbreviation cccDNA denotes covalently closed circular DNA, HBeAg HBV core-related antigen, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, and ULN upper limit of the normal range.
† Quantitative HBsAg levels are derived from baseline data in clinical trials of small interfering RNA. Ranges can vary significantly in HBeAg-negative patients, depending on the HBV genotype and HBsAg expression.
‡ The low number of infected cells in some HBeAg-negative patients, the low cccDNA copy number (1 to 10 per infected cell), and the lack of standards for quantitation allow only a qualitative assumption of cccDNA copy number.
§ The presence of integrated HBV DNA is usually assumed.
<table>
<thead>
<tr>
<th>Variable</th>
<th>HBeAg-Positive Chronic HBV Infection</th>
<th>HBeAg-Positive Chronic Hepatitis B</th>
<th>HBeAg-Negative Chronic HBV Infection</th>
<th>HBeAg-Negative Chronic Hepatitis B</th>
<th>“Gray Zone”</th>
<th>Occult Hepatitis B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other phase names</td>
<td>Immune tolerant</td>
<td>Immune (re)active</td>
<td>Inactive carrier state</td>
<td>HBeAg-negative disease</td>
<td>Indeterminate</td>
<td>Negative</td>
</tr>
<tr>
<td>Serologic testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBsAg</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Quantitative HBsAg (logₐ₁₀ IU/ml)</td>
<td>3.5–4.5</td>
<td>3.5–4.5</td>
<td>2.5–3.5</td>
<td>2–3</td>
<td>2–3</td>
<td>Negative</td>
</tr>
<tr>
<td>HBeAg</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>HBe antibodies</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>May be positive</td>
</tr>
<tr>
<td>HBV DNA (IU/ml)</td>
<td>Typically &gt;10⁰</td>
<td>Typically &gt;10⁰ to 10⁷</td>
<td>&lt;10⁰</td>
<td>Typically &gt;10⁰ to ≤10⁷</td>
<td>2 × 10⁰ (3.3 log₁₀) to 2 × 10⁰ (4.3 log₁₀)</td>
<td>Low, at detection limit</td>
</tr>
<tr>
<td>Alanine aminotransferase</td>
<td>Near ULN</td>
<td>Elevated</td>
<td>Near ULN</td>
<td>Elevated</td>
<td>Fluctuates near ULN</td>
<td></td>
</tr>
<tr>
<td>Histologic features on liver biopsy</td>
<td>Minimal necroinflammation or fibrosis</td>
<td>Moderate-to-severe necroinflammation or fibrosis</td>
<td>Minimal necroinflammation and fibrosis</td>
<td>Moderate-to-severe necroinflammation or fibrosis</td>
<td>Minimal or low necroinflammation; fibrosis can be present</td>
<td></td>
</tr>
<tr>
<td>cccDNA (assumed copy no./cell)</td>
<td>Relatively high</td>
<td>Relatively high</td>
<td>Relatively low, or transcriptional activity</td>
<td>Relatively low, or transcriptional activity</td>
<td>Relatively low, or transcriptional activity</td>
<td>Data uncertain</td>
</tr>
<tr>
<td>Integrated HBV DNA‡</td>
<td>Present</td>
<td>Present</td>
<td>Present accounts for majority of HBeAg</td>
<td>Present accounts for majority of HBeAg</td>
<td>Present</td>
<td>Present</td>
</tr>
<tr>
<td>HBeAg level</td>
<td>High</td>
<td>High</td>
<td>Low or undetected</td>
<td>Lower than HBeAg-positive states</td>
<td>May be detected</td>
<td>Data not available</td>
</tr>
<tr>
<td>HBV RNA level</td>
<td>High</td>
<td>High</td>
<td>Low or undetected</td>
<td>Lower than HBeAg-positive states</td>
<td>May be detected</td>
<td>Data not available</td>
</tr>
</tbody>
</table>

* The abbreviation cccDNA denotes covalently closed circular DNA, HBeAg HBV core-related antigen, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, and ULN upper limit of the normal range.
† Quantitative HBsAg levels are derived from baseline data in clinical trials of small interfering RNA. Ranges can vary significantly in HBeAg-negative patients, depending on the HBV genotype and HBsAg expression.
‡ The low number of infected cells in some HBeAg-negative patients, the low cccDNA copy number (1 to 10 per infected cell), and the lack of standards for quantitation allow only a qualitative assumption of cccDNA copy number.
§ The presence of integrated HBV DNA is usually assumed.

Figure 1 - Agents Approved by the U.S. FDA for the Treatment of Hepatitis B Virus (HBV) Infection

This graphic shows the timeline of FDA approval in the United States for agents used to treat chronic HBV infection.
Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion

Shilpa Vasishta, MD, Douglas Dieterich, MD, Michael Mullen, MD, and Judith Aberg, MD

1. Four individuals with HBV infection or reactivation after ART switch identified
2. Two had HBV susceptibility, 1 had core Ab reactivity, and 1 had surface Ag reactivity preswitch
3. Two presented with fulminant hepatitis, with 1 required liver transplantation
4. **Takeaway:** Careful patient selection and monitoring needed when considering two-drug antiretroviral therapy for HIV, including assessment of serologies, vaccination and confirmation of immunity, and risk stratification
## HBV Treatment Recommendation Based on Major Organization Guidelines

<table>
<thead>
<tr>
<th>Indication</th>
<th>AASLD 2018</th>
<th>APASL 2015</th>
<th>EASL 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decompensated Cirrhosis</td>
<td>• Treat all <em>and</em> Refer for liver transplantation</td>
<td>• Treat all</td>
<td>• Treat all</td>
</tr>
<tr>
<td>Compensated Cirrhosis</td>
<td>• Treat all</td>
<td>• Treat if:</td>
<td>• Treat all</td>
</tr>
<tr>
<td></td>
<td>- HBV DNA &gt;2,000 IU/mL</td>
<td>- ALT elevated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without Cirrhosis</td>
<td>- ALT elevation (≥2x ULN&lt;sup&gt;2&lt;/sup&gt;) or Significant histologic disease&lt;sup&gt;4&lt;/sup&gt; and - HBV DNA &gt;2000 IU/mL if HBeAg-negative - HBV DNA &gt;20,000 IU/mL if HBeAg-positive</td>
<td>- ALT elevation (&gt;2x ULN&lt;sup&gt;3&lt;/sup&gt;) or Significant histologic disease&lt;sup&gt;4&lt;/sup&gt; and - HBV DNA &gt;2000 IU/mL if HBeAg-negative - HBV DNA &gt;20,000 IU/mL if HBeAg-positive</td>
<td>- Treat if: - ALT &gt;40 IU/L, HBV DNA &gt;2000 IU/mL, and biopsy evidence of at least moderate necroinflammation (or at least moderate fibrosis) or - HBV DNA &gt;2000 IU/mL and biopsy evidence of at least moderate fibrosis or - HBV DNA &gt;20,000 IU/mL and ALT &gt;2x ULN&lt;sup&gt;3&lt;/sup&gt; regardless of degree of fibrosis</td>
</tr>
</tbody>
</table>

*1 Regardless of HBV DNA, ALT, or HBeAg status; 2 Upper limit of normal, defined as ALT 35 for men, 25 for women; 3 Defined as ALT 40 for both men and women; 4 Defined as at least moderate necroinflammation or at least moderate fibrosis according to histopathologic grading/staging.

---

**Figure 4 - Guidelines for the Treatment of Chronic Hepatitis B**

**Abbreviations:** AASLD = American Association for the Study of Liver Diseases; APASL = Asian Pacific Association for the Study of the Liver; EASL = European Association for the Study of the Liver; ALT = alanine aminotransferase; ULN = upper limit of normal

Adding Insult to Injury… Defining “Normal” ALT

- AASLD and EASL do NOT recommend using reference laboratory cutoffs to define “normal” values.
  - AASLD ULN
    - 35 U/L for Males
    - 25 U/L for Females
  - EASL ULN
    - 40 IU/L for Males and Females

- ALT levels that lower than these limits STILL may not exclude significant liver disease

- Elevated ALT or AST above ULN is associated with increased liver-related mortality
HBV Outline

- Evolving Epidemiology
- Current Management of HBV
- Evolving Approaches to Management and Treatment
## Reframing the Problem

<table>
<thead>
<tr>
<th>Virus</th>
<th>Disease Type</th>
<th>Infection Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>Immunodeficiency syndrome</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Hepatitis C Virus</td>
<td>Inflammatory liver disease</td>
<td>Viral infection</td>
</tr>
<tr>
<td>Hepatitis B Virus</td>
<td>Inflammatory liver disease</td>
<td>Viral infection</td>
</tr>
</tbody>
</table>
Facts About HBV That “Doesn’t Warrant Treatment”

- Increases risk of hepatocellular carcinoma, even in noncirrhotic
- Increases risk of other solid malignancies
- Increases risk of multiple autoimmune conditions
- Increases risk of fulminant liver disease on immunosuppression
- Contribute to stigma and other patient reported outcomes
What If… In a Simpler (HBV Treatment) World?

- **Age and Viral Load Driven Criteria**
  - If age <30, treat if HBV DNA >2000 IU/mL and ALT > ULN
  - If age ≥30, treat if HBV DNA >2000 IU/mL
  - Treat all with HBV with cirrhosis
  - Treat all with HBV and HIV

- **Liver Inflammation Driven Criteria**
  - If ALT > ULN, treat
  - If ALT normal, treat if HBV DNA >2000 IU/mL
  - Treat all with HBV with cirrhosis
  - Treat all with HBV and HIV
Hepatitis B Management: Guidance for the Primary Care Provider

The purpose of this document is to provide simplified, up-to-date, and readily accessible guidance for primary care medical providers related to the prevention, diagnosis, and management of hepatitis B virus (HBV) infection, including hepatocellular carcinoma surveillance.

About the HBV Primary Care Workgroup
This guidance was developed by the Hepatitis B Primary Care Workgroup, a multidisciplinary panel of national experts in the field of viral hepatitis B, including representation from hepatology, infectious diseases, pharmacy, primary care, public health, and other national organizations. The workgroup was organized by the National Taskforce on Hepatitis B in partnership with the San Francisco Hep B Free — Bay Area and Project ECHO™ and did not receive any outside funding.

Collaboration with University of Washington
This guidance was produced in collaboration with the University of Washington’s National Hepatitis Training Center (HTC). The UW HTC will host and feature the most current version of these guidelines on the free Hepatitis B Online website (hepatitisb.uw.edu). The UW HTC is funded by the Centers for Disease Control and Prevention (CDC).


TABLE OF CONTENTS
- Chronic Hepatitis B Testing and Management Algorithm 2
- Hepatitis B Virus (HBV) Serology Interpretation and Management 3
- Initial Evaluation of the HBsAg+ Patient 4
- Counseling of the HBsAg+ Patient 4
- Management of the HBsAg+ Patient 5
- Preferred Antiviral Treatment of the HBsAg+ Patient 6
- Hepatocellular Carcinoma (HCC) Surveillance 7
- Perinatal HBV Management 8
- Selected References 9
- HBV Primary Care Workgroup Members 10
- Disclosures 11

HBV Primary Care Workgroup

HBV GUIDANCE CO-CHAIRS
Amy S. Tang, MD
Karla Thornton, MD, MPH

HEPATOLOGY
Eric W. Chiu, MD, MPH
Robert G. Gish, MD
Anna S. Loh, MD
Brian J. McMahen, MD
Lewis B. Roberts, MD, CH, PhD
Norah A. Terrault, MD, MPH

INFECTIOUS DISEASES
Camilla S. Graham, MD, MPH
David H. Spach, MD
Mark S. Sulkowski, MD
Karla Thornton, MD, MPH

PHARMACY
Paulina Deming, PharmD

PRIMARY CARE
Richard Andrews, MD, MPH
Amy S. Tang, MD
Grace Wang, MD, MPH
Su Wang, MD, MPH

PUBLIC HEALTH
Moon S. Oh, MD, PhD, MPH
Chari Cohen, DrPH, MPH
Stuart Feng, MD
Aaron M. Harris, MD, MPH
Rita K. Kwakara, MD, MPH
Richard So, MPH, MPA
Ann Winters, MD

Additional Workgroup Support
Melanie Bird, PhD
Jennifer Lim
Amir Qaseem, MD, PhD
Amy Tang, PhD, M.Ed
HBV Life Cycle

HBV Life Cycle Updated

Dusheiko G et al. NEJM 2023.
Dusheiko G et al. NEJM 2023.
### Table 2: New Anti-HBV Compounds in Clinical Development.

<table>
<thead>
<tr>
<th>Type and Compound</th>
<th>Originator</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capsid assembly modulators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vebicovir (ABI-H0731)</td>
<td>Assembly Biosciences</td>
<td>Phase 2 terminated</td>
</tr>
<tr>
<td>ABI-H3733</td>
<td></td>
<td>Phase 1</td>
</tr>
<tr>
<td>ABI-4334</td>
<td></td>
<td>Preclinical studies</td>
</tr>
<tr>
<td>Morphothiadin (GLS4)</td>
<td>HEC Pharma</td>
<td>Phase 2</td>
</tr>
<tr>
<td>JNJ-6379</td>
<td>Janssen</td>
<td>Phase 2b</td>
</tr>
<tr>
<td>EDP-514</td>
<td>Enanta</td>
<td>Phase 2</td>
</tr>
<tr>
<td>RG7907</td>
<td>Roche</td>
<td>Phase 2</td>
</tr>
<tr>
<td>QL-007</td>
<td>Qilu</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Canocapavir</td>
<td>Zhimeng Biopharma</td>
<td>Not available</td>
</tr>
<tr>
<td>ALG-000184</td>
<td>Aligos Therapeutics</td>
<td>Phase 1</td>
</tr>
<tr>
<td>AB-836</td>
<td>Arbutus</td>
<td>Phase 1 and 2</td>
</tr>
<tr>
<td>VNRX-9945</td>
<td>Venatorx</td>
<td>Phase 1 terminated</td>
</tr>
<tr>
<td>O7049839</td>
<td>Roche</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

**Antisense oligonucleotides**

- Bepirovirsen (GSK3228836) | GSK | Phase 2
- RO7062931 | Roche | Phase 1
- ALG-020572-401 | Aligos Therapeutics | Phase 1

**Nucleic acid polymers:**

- REP 2139, REP 2165 | Replicor | Phase 2

**Active-site polymerase inhibitor:**

- ATI-2173 | Antios | Phase 2

**Entry inhibitor: bulevirtide**

- Gilead | Phase 3 (hepatitis D)

**Transcriptional inhibitor: nitazoxanide**

- Romark Laboratories/Lupin | Phase 2

* The information on study status is from ClinicalTrials.gov, accessed December 4, 2022.

† The abbreviation siRNA denotes small interfering RNA.
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection


CONCLUSIONS
In this phase 2b trial, bepiroviren at a dose of 300 mg per week for 24 weeks resulted in sustained HBsAg and HBV DNA loss in 9 to 10% of participants with chronic HBV infection. Larger and longer trials are required to assess the efficacy and safety of bepiroviren. (Funded by GSK; B-Clear ClinicalTrials.gov number, NCT04449029.)

Figure 1. Trial Design.
Take Home Points

1. HBV has a huge health impact on global and domestic populations, who are often at-risk and underserved.

2. Universal HBV screening is now recommended, along with more inclusive HBV vaccination guidelines.

3. Evolving HBV treatment algorithms and new antiviral therapies are transforming clinical care and the opportunities for clinical, research, and scholarly activity.
Thank You!

Questions?

cody.a.chastain@vumc.org
What questions or comments do you have?

Very good presentation! Would love to see HBV testing encouraged more.

What do you think about routine antibody testing after vaccine series?

Great Presentation, thank you for such a wide scope of information. I feel has become a tool that I can use when encountering newly diagnosed or co-infected HBV & HIV persons.

None very good presentation.

Great presentation!